0000950157-13-000130.txt : 20130314 0000950157-13-000130.hdr.sgml : 20130314 20130314072627 ACCESSION NUMBER: 0000950157-13-000130 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20130314 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20130314 DATE AS OF CHANGE: 20130314 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QUEST DIAGNOSTICS INC CENTRAL INDEX KEY: 0001022079 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 161387862 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12215 FILM NUMBER: 13689107 BUSINESS ADDRESS: STREET 1: 3 GIRALDA FARMS CITY: MADISON STATE: NJ ZIP: 07940 BUSINESS PHONE: 9735202700 MAIL ADDRESS: STREET 1: 3 GIRALDA FARMS CITY: MADISON STATE: NJ ZIP: 07940 FORMER COMPANY: FORMER CONFORMED NAME: CORNING CLINICAL LABORATORIES INC DATE OF NAME CHANGE: 19960903 8-K 1 form8k.htm CURRENT REPORT form8k.htm
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 14, 2013
 
Quest Diagnostics Incorporated
(Exact name of registrant as specified in its charter)
 
 
 Delaware
(State or other jurisdiction of incorporation)


001-12215
16-1387862
(Commission File Number)
(IRS Employer Identification No.)
   
Three Giralda Farms
  
Madison, NJ
07940
(Address of principal executive offices)
(Zip Code)

(973) 520-2700
(Registrant’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 
 
Item 8.01. Other Events.
 
On March 14, 2013, Quest Diagnostics Incorporated (the “Company”) issued a press release announcing the Company’s Chief Financial Officer Transition Plan.  A copy of the press release is attached hereto as Exhibit 99.1.
 
Item 9.01. Financial Statements and Exhibits.
                      
  (d)  Exhibit   Description
     99.1  
Press release of Quest Diagnostics Incorporated, dated March 14, 2013, announcing the Company’s Chief Financial Officer Transition Plan.
 
 
 
 
 
 
 
 
 
 
SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

March 14, 2013
 
  QUEST DIAGNOSTICS INCORPORATED  
       
 
By:
/s/ William J. O’Shaughnessy, Jr.  
    Name: William J. O’Shaughnessy, Jr.   
    Title:   Assistant General Counsel and Secretary  
       

EX-99.1 2 ex99-1.htm PRESS RELEASE ex99-1.htm
Exhibit 99.1
 
Quest Diagnostics Announces Chief Financial Officer Transition Plan
 
 
MADISON, N.J., March 14, 2013 -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced that Robert A. Hagemann, Senior Vice President and Chief Financial Officer, plans to leave the company at the end of May 2013.  The company is launching a search for a new CFO that will consider both internal and external candidates, and Mr. Hagemann will assist in identifying his successor.  Mr. Hagemann will continue in his capacity as CFO through May 31, 2013, unless a successor is named and the transition is complete before that date.
 
"We are grateful to Bob for his service to Quest Diagnostics and the leadership he has demonstrated since joining the company in 1992," said Steve Rusckowski, President and Chief Executive Officer. "Quest Diagnostics has benefited enormously from Bob’s financial and business expertise over his long tenure with the company. On behalf of the entire organization, we thank Bob for his many contributions and wish him well in all his future endeavors."

“It has been incredibly gratifying to have had a hand in building the world’s leader in diagnostic information services,” said Mr. Hagemann. “Quest Diagnostics has a very bright future. We have a new, clear strategy and an outstanding team that is leading the company forward. At this point, after 21 years with the company and almost 15 years as the CFO, we agreed now is a good time for a change. I thank everyone at Quest for the tremendous support I have received over the years.”
 
About Quest Diagnostics
 
 
Quest Diagnostics is the world's leading provider of diagnostic information services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic information services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at QuestDiagnostics.com. Follow us at Facebook.com/QuestDiagnostics and Twitter.com/QuestDX.
 
# # #